Axitinib Impurity 45

Basic Information

View in Editor

CAS Number

2527-66-4

Molecular Formula

C8H7NOS

Molecular Weight

165.22 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Dyes and Pigments Organic Dyes

Basic Physical Properties

Melting Point

51-52 ºC

SMILES

View in Editor

CN1C(=O)C2=CC=CC=C2S1

InChI

InChI=1S/C8H7NOS/c1-9-8(10)6-4-2-3-5-7(6)11-9/h2-5H,1H3

InChIKey

RDWXSJCICPOOKO-UHFFFAOYSA-N

LogP

1.6

Topological Polar Surface Area

22.0 Å²

Hydrogen Bond Donor/Acceptor

0 / 2

Complexity

183

Synonyms & References

English

KUC103657N
2-Methyl-1,2-benzisothiazolin-3-one
Mbit
n-methyl-1,2-benzisothiazolin-3-one
Q27269263
2-methyl-1,2-benzisothiazol-3(2H)-one
2-methyl-1,2-benzothiazol-3-one
81PV9X5Y68
A51204
BDBM61908
2-Methyl-1,2-benzoisothiazolin-3-one
SCHEMBL50008
NSC520046
2-Methy-l Benzisothiazolin-3-one
SY251953
NSC-520046
UNII-81PV9X5Y68
MLS003116052
NS00019658
KSC-325-045
InChI=1/C8H7NOS/c1-9-8(10)6-4-2-3-5-7(6)11-9/h2-5H,1H
CS-0155480
DTXSID00325841
2-Methylbenzo[d]isothiazol-3(2H)-one
RDWXSJCICPOOKO-UHFFFAOYSA-N
KUC103657N-02
2-methyl-2,3-dihydro-1,2-benzothiazol-3-one
A903146
cid_351236
AS-63031
1,2-benzisothiazol-3(2H)-one, 2-methyl-

MDL Number

MFCD02311302

FAQ

What regulatory guidelines apply to Axitinib Impurity 45 (CAS: 2527-66-4)?

Axitinib Impurity 45 (CAS: 2527-66-4) is subject to various regulatory guidelines including GHS classification for hazardous materials, REACH regulations for registration, evaluation, and authorization of chemical substances, and FDA/EPA guidelines for safety, handling, and disposal. It is important to comply with these regulations to ensure safety and legal compliance.

Are there alternatives to Axitinib Impurity 45 (CAS: 2527-66-4) in synthesis?

In the synthesis of Axitinib Impurity 45 (CAS: 2527-66-4), alternatives such as using isomers or analogs of Axitinib may be considered. Common alternative reagents include 2-methylbutane and other similar compounds. It is crucial to evaluate these alternatives for their efficacy and regulatory compliance.

What is the market or research trend for Axitinib Impurity 45 (CAS: 2527-66-4)?

The market for Axitinib Impurity 45 (CAS: 2527-66-4) is driven by ongoing research and development in oncology. Recent trends indicate increasing demand for impurities in drug development and clinical trials. Researchers are focusing on understanding the effects of these impurities on drug efficacy and safety. Price trends suggest a steady demand with slight fluctuations based on market supply and demand dynamics.

How should waste containing Axitinib Impurity 45 (CAS: 2527-66-4) be handled?

Waste containing Axitinib Impurity 45 (CAS: 2527-66-4) should be handled according to the guidelines for hazardous waste management. Collection and storage should be done in appropriate containers, and incineration or professional waste disposal methods should be employed. Environmental protection measures include ensuring proper containment to prevent leaks and adhering to local environmental regulations. It is essential to consult with a waste management specialist to ensure safe and compliant disposal.